Highlights from ASCO 2016 for myeloproliferative neoplasms

2 Views

07/29/23

Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ talks about his highlights from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. In particular, Dr Mesa discusses why he is looking forward to hearing about key drugs in disease areas that are relevant to myeloproliferative neoplasms (MPNs), which include acute leukemias and myelodysplastic syndrome (MDS). According to Dr Mesa, the data on immunotherapy and intercellular therapy in these areas is of interest. For MPNs, he highlights the five year update on the safety and efficacy of ruxolitinib.